These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29966778)

  • 41. Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas.
    Wu Y; Liu C; Yu S; Gao H; Li Z; Li C; Zhang Y
    Oncol Rep; 2016 May; 35(5):2991-9. PubMed ID: 26935389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
    Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
    Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlations between the expression of molecules in the TGF-β signaling pathway and clinical factors in adamantinomatous craniopharyngiomas.
    Jin L; Cai K; Wu W; Xiao Y; Qiao N; Liu F; Ru S; Cao L; Zhu H; Bai J; Liu C; Li C; Zhao P; Zhang Y; Gui S
    Front Endocrinol (Lausanne); 2023; 14():1167776. PubMed ID: 37854185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
    Lidhar K; Korbonits M; Jordan S; Khalimova Z; Kaltsas G; Lu X; Clayton RN; Jenkins PJ; Monson JP; Besser GM; Lowe DG; Grossman AB
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3823-30. PubMed ID: 10523037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human pituitary adenomas express endogenous inhibin subunit and follistatin messenger ribonucleic acids.
    Alexander JM; Swearingen B; Tindall GT; Klibanski A
    J Clin Endocrinol Metab; 1995 Jan; 80(1):147-52. PubMed ID: 7829603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. c‑Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer.
    Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
    Mol Med Rep; 2018 Jun; 17(6):8180-8188. PubMed ID: 29693707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
    Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
    Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of EpCAM and Trop2 in pituitary adenomas.
    Chen X; Pang B; Liang Y; Xu SC; Xin T; Fan HT; Yu YB; Pang Q
    Int J Clin Exp Pathol; 2014; 7(11):7907-14. PubMed ID: 25550831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The identification of human pituitary adenoma-initiating cells.
    Manoranjan B; Mahendram S; Almenawer SA; Venugopal C; McFarlane N; Hallett R; Vijayakumar T; Algird A; Murty NK; Sommer DD; Provias JP; Reddy K; Singh SK
    Acta Neuropathol Commun; 2016 Nov; 4(1):125. PubMed ID: 27894339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of somatostatin receptor subtypes in primary and recurrent gonadotropinomas: are somatostatin receptors involved in pituitary adenoma recurrence?
    Pisarek H; Kunert-Radek J; Radek M; Swietoslawski J; Winczyk K; Pawlikowski M
    Neuro Endocrinol Lett; 2011; 32(1):96-101. PubMed ID: 21407161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
    Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
    Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.
    Butz H; Németh K; Czenke D; Likó I; Czirják S; Zivkovic V; Baghy K; Korbonits M; Kovalszky I; Igaz P; Rácz K; Patócs A
    Pathol Oncol Res; 2017 Jul; 23(3):633-641. PubMed ID: 28004354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in human pituitary adenomas.
    Fujiwara K; Ikeda H; Yoshimoto T
    Clin Neuropathol; 1998; 17(1):19-26. PubMed ID: 9496536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas.
    Chen L; Liu Y; Hou Y; Kato Y; Sano H; Kanno T
    Neurosci Lett; 2007 Apr; 417(1):30-5. PubMed ID: 17398005
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
    Ruebel KH; Leontovich AA; Jin L; Stilling GA; Zhang H; Qian X; Nakamura N; Scheithauer BW; Kovacs K; Lloyd RV
    Endocrine; 2006 Jun; 29(3):435-44. PubMed ID: 16943582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers.
    Supic G; Kozomara R; Jovic N; Zeljic K; Magic Z
    Oral Dis; 2011 Nov; 17(8):794-800. PubMed ID: 21819494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Smad3 and phospho-Smad3 are potential markers of invasive nonfunctioning pituitary adenomas.
    Liu C; Li Z; Wu D; Li C; Zhang Y
    Onco Targets Ther; 2016; 9():2265-71. PubMed ID: 27143922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms.
    Schittenhelm J; Psaras T; Meyermann R; Honegger J; Beschorner R
    Folia Neuropathol; 2010; 48(2):75-80. PubMed ID: 20602288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.
    Gong J; Zhao Y; Abdel-Fattah R; Amos S; Xiao A; Lopes MB; Hussaini IM; Laws ER
    Pituitary; 2008; 11(1):37-48. PubMed ID: 17768685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.